The effect of renin angiotensin system on tamoxifen resistance

Medical Hypotheses

Volumn 77, Issue 1, 2011, Pages 152-155

  Namazi, Soha ^a   Ardeshir Rouhani Fard, Shirin ^a   Abedtash, Hamed ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN RECEPTOR; IDOXIFENE; LOSARTAN; PERINDOPRIL; TAMOXIFEN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; HEART PROTECTION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RENIN-ANGIOTENSIN SYSTEM; TAMOXIFEN;

EID: 79958043448     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.04.004     Document Type: Article

References (47)

1. Bäumer A.T., Wassmann S., Ahlbory K., et al. Reduction of oxidative stress and At1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol 2001, 134:579-584.
2. Lewis J.S., Jordan V.C. Selective estrogen receptor modulators (serms): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005, 591:247-263.
3. Milano A., Lago L.D., Sotiriou C., Piccart M., Cardoso F. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer 2006, 42:2692-2705.
4. Schafer J.M., Bentrem D.J., Takei H., Gajdos C., Badve S., Jordan V.C. Mechanism of drug resistance to tamoxifen in breast: cancer. J Steroid Biochem Mol Biol 2002, 83:75-83.
5. Fichtner I., Becker M., Zeisig R., Sommer A. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance. Eur J Cancer 2004, 40:845-851.
6. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab 2005, 16:293-299.
7. Doi C., Egashira N., Kawabata A. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 2010, 10:67.
8. Suarez C., Díaz-Torga G., González-Iglesias A., Cristina C., Becu-Villalobos D. Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia. Am J Physiol Endocrinol Metab 2004, 286:E786-E794.
9. Tahmasebi M., Barker S., Puddefoot J.R., Vinson G.P. Localisation of renin-angiotensin system (Ras) components in breast. Br J Cancer 2006, 95:67-74.
10. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008, 264:224-236.
11. Ager E.I., Neo J., Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29:1675-1684.
12. Abali H., Güllü I.H., Engin H., Haznedaroĝlu I.C., Erman M., Tekuzman G. Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses 2002, 59:344-348.
13. Hofseth L.J., Wargovich M.J. Inflammation, cancer, and targets of Ginseng. J Nutr 2007, 137:183s-185s.
14. Ager E.I., Chong W.W., Wen S.W., Christophi C. Targeting the angiotensin II type 2 receptor (At2r) in colorectal liver metastases. Cancer Cell Int 2010, 10:19.
15. Munk V.C., De Miguel L.S., Petrimpol M., et al. Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an At2-B2 receptor pathway. Hypertension 2007, 49:1178-1185.
16. Sane D.C., Anton L., Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 2004, 7:193-201.
17. Li H., Qi Y., Li C., et al. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther 2009, 8:3255-3265.
18. Pickel L., Matsuzuka T., Doi C., et al. Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther 2010, 9:277-285.
19. Dolley-Hitze T., Jouan F., Martin B., et al. Angiotensin-2 Receptors (At1-R And At2-R), New prognostic factors for renal clear-cell carcinoma. Br J Cancer 2010, 103:1698-705.
20. Clere N., Corre I., Faure S., et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 2010, 127:2279-2291.
21. De Paepe B., Verstraeten V.L., De Potter C.R., Bullock G.R. Increased angiotensin II type-2 receptor density in hyperplasia DCIS and invasive carcinoma of the breast is paralleled with increased INOS expression. Histochem Cell Biol 2002, 117:13-19.
22. Koh W.P., Yuan J.M., Sun C.L., et al. Angiotensin I-converting enzyme (ace) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003, 63:573-578.
23. Hii S., Nicol D., Gotley D., Thompson L., Green M., Jonsson J. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998, 77:880-883.
24. Arafat H.A., Gong Q., Chipitsyna G., Rizvi A., Saa C.T., Yeo C.J. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007, 204:996-1005.
25. Yasumatsu R., Nakashima T., Masuda M., et al. Effects of the angiotensin-i converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 2004, 130:567-573.
26. Koh W.P., Yuan J.M., Berg D.V.D., Lee H.P., Yu M.C. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 2005, 26:459-464.
27. Kosugi M., Miyajima A., Kikuchi E., Horiguchi Y., Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006, 12:2888-2893.
28. Kosaka T., Miyajima A., Takayama E., et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2006, 67:41-49.
29. Hong H., Liu J., Chan P., et al. 17β-estradiol downregulates angiotensin-II induced endothelin-1 gene expression in rat aortic smooth muscle cells. J Biomed Sci 2004, 11:27-36.
30. Kim J.K., Levin E.R. Estrogen signaling in the cardiovascular system. Nucl Recept Signal 2006, 4.
31. Xue B., Pamidimukkala J., Lubahn D.B., Hay M. Estrogen receptor-α mediates estrogen protection from angiotensin ii-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol 2007, 292:H1770-H1776.
32. Wu M., Han M., Li J., et al. 17β-estradiol inhibits angiotensin II-induced cardiac myofibroblast differentiation. Eur J Pharmacol 2009, 616:155-159.
33. Ogita G., Node K., Liao Y., et al. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 2004, 43:237-242.
34. Nickenig G., Bäumer A.T., Grohè C., et al. Estrogen modulates at1 receptor gene expression in vitro and in vivo. Circulation 1998, 97:2197-2201.
35. González-Zuloeta Ladd A.M., Vásquez A.A., Siemes C., et al. Differential roles of angiotensinogen and angiotensin receptor type 1 polymorphisms in breast cancer risk. Breast Cancer Res Treat 2007, 101:299-304.
36. Tostes R.C., Nigro D., Fortes Z.B., Carvalho M.H.C. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003, 36:1143-1158.
37. Nickenig G., Harrison D.G. The At1-type angiotensin receptor in oxidative stress and atherogenesis part II: At1 receptor regulation. Circulation 2002, 105:530-536.
38. Stewart J.A., Cashatt D.O., Borck A.C., Brown J.E., Carver W.E. 17β-estradiol modulation of angiotensin II-stimulated response in cardiac fibroblasts. J Mol Cell Cardiol 2006, 41:97-107.
39. Dean S.A., Tan J., O'brien E.R., Leenen F.H.H. 17β-estradiol downregulates tissue angiotensin-converting enzyme and Ang II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 2005, 288:R759-R766.
40. Zheng W., Shi M., Yoo S.E., Ji H., Roesch D.M. Estrogens contribute to a sex difference in plasma potassium concentration: a mechanism for regulation of adrenal angiotensin receptors. Gend Med 2006, 3:43-53.
41. Wu Z., Maric C., Roesch D.M., Zheng W., Verbalis J.G., Sandberg K. Estrogen regulates adrenal angiotensin At1 receptors by modulating at1 receptor translation. Endocrinology 2003, 144:3251-3261.
42. Rogers J.L., Mitchell A.R., Maric C., Sandberg K., Myers A., Mulroney S.E. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol 2007, 292:R794-R799.
43. Armando I., Jezova M., Juorio A.V., et al. Estrogen upregulates renal angiotensin II At2 receptors. Am J Physiol Renal Physiol 2002, 283:F934-F943.
44. Macova M., Armando I., Zhou J., et al. Estrogen reduces aldosterone, upregulates adrenal angiotensin II At2 receptors and normalizes adrenomedullary Fra-2 in ovariectomized rats. Neuroendocrinology 2008, 88:276-286.
45. Brosnihan K.B., Hodgin J.B., Smithies O., Maeda N., Gallagher P. Tissue-specific regulation of Ace/Ace2 And At1/At2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-α knock-out mice. Exp Physiol 2008, 93:658-664.
46. Namazi S., Ardeshir Rouhani Fard S., Abedtash H. Role of endothelin-1 in tamoxifen resistance. Mechanism for a new possible treatment strategy in breast cancer. Med Hypotheses 2008, 70:109-111.
47. Shaw L.E., Sadler A.J., Pugazhendhi D., Darbre P.D. Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, Ici 182, 780) in Mcf-7 human breast cancer cells. J Steroid Biochem Mol Biol 2006, 99:19-32.